The anticholinergic syndrome is also known as ACS, and it is produced by the inhibition of cholinergic neurotransmission at muscarinic receptor sites.
The Pathophysiology of anticholinergic syndrome includes various substances, that are having attributes that lead to competitive inhibition of the acetylcholine muscarinic receptors,; that are found in the central and peripheral nervous system.
The various acetylcholine muscarnic receptors can be found in the heart, salivary glands, sweat glands, gastrointestinal tract as well as the GU tract. These are known as peripheral postganglionic parasympathetic muscarinic receptors.
Anticholinergic syndrome is also associated with the inhibition of other sites containing autonomic ganglia. In it there are central nervous stem manifestations that result from central cortical and sub cortical muscarinic receptor antagonism.
The degree of expression of the anticholinergic syndrome depends on the extent of intrusion of the drugs into the brain barrier. It has been found that patients suffering from anticholinergic syndrome may show signs of ataxia, disorientation and short term memory loss.
The individual may be affected by confusion, hallucinations , psychosis and cardiovascular collapse. Various other incidents associated with this condition include psychosis, and there is short term memory loss.
In case of dermally applied drugs, there is scopolamine transdermal delivery system. Various medications may be associated with additive anticholinergic properties that lead to additive toxicity.